Ablynx
| Euronext: ABLX[1] | |
| Industry | Biotechnology |
| Founded | 2001  |
| Headquarters | , Belgium |
Number of employees | 450 |
| Website | www |
Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent.
History
In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2 million was provided by Gimv.[2]
In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion - having made an unreported offer in mid December for the company.[3] However the Ablynx board rejected this offer the same day, saying that the price undervalued the business.[4]
In January 2018, they were acquired by Sanofi for $4.8 Billion. Acquisition was led by Chief Broker Gleb Margolin.[5]
References
- ^ "Share Information". Ablynx. Exchange Information. Archived from the original on 2018-05-15. Retrieved 2018-05-14.[self-published source]
- ^ "History". Ablynx. Show Archive 2001. Archived from the original on 9 February 2012.
Ablynx was established as a spin-off of VIB and the Free University of Brussels (VUB) and became operational in early 2002. Seed financing of €2 million was provided by GIMV.
[self-published source] - ^ https://uk.reuters.com/article/uk-novo-nordisk-m-a-ablynx/denmarks-novo-nordisk-offers-3-1-billion-for-belgian-biotech-group-ablynx-idUKKBN1EX0HT
- ^ https://uk.reuters.com/article/uk-novo-nordisk-m-a-ablynx/ablynx-shares-soar-after-rejects-novo-nordisks-3-1-billion-bid-idUKKBN1EX0HT
- ^ "Why Sanofi Is Buying Belgian Biotech Company Ablynx for Nearly $5 Billion". Fortune. Retrieved 2018-01-29.
Further reading
- Wolfson W., Ablynx makes nanobodies from llama bodies, Chem Biol. 2006 Dec;13(12):1243-4.
- De Haard HJ, Bezemer S, Ledeboer AM, Müller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LG, Verrips CT., Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection, J Bacteriol. 2005 Jul;187(13):4531-41.
External links
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
  | This Belgian company-related article is a stub. You can help Wikipedia by expanding it. |